Aktuellt
SENASTE
Redeye comments on Nanexa’s preliminary key financial information for Q3. We will return with a more thorough analysis in connection to the outcome of the ongoing rights issue, wherein our new base case will also consider the dilutive effect of the capital injection.
LÄS MER
